<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA Dermatology: Pain Assessment Topic Collection</title>
    <link>http://archderm.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Mon, 31 Dec 2012 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 01 Jan 2013 00:50:18 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@archderm.jamanetwork.com</managingEditor>
    <webMaster>webmaster@archderm.jamanetwork.com</webMaster>
    <item>
      <title>Safety of a Novel Microneedle Device Applied to Facial Skin A Subject- and Rater-Blinded, Sham-Controlled, Randomized Trial  Safety of an MND on Facial Skin </title>
      <link>http://archderm.jamanetwork.com/article.aspx?articleID=1149925</link>
      <pubDate>Fri, 01 Jun 2012 00:00:00 GMT</pubDate>
      <author>Hoesly FJ, Borovicka J, Gordon J, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Objective&lt;/div&gt;To assess the safety of a novel microneedle device on facial skin of healthy individuals of all Fitzpatrick skin types.&lt;div class="boxTitle"&gt;Design&lt;/div&gt;Subject- and live rater–blinded, sham-controlled, randomized trial.&lt;div class="boxTitle"&gt;Setting&lt;/div&gt;University-based ambulatory dermatology service providing both primary and referral care.&lt;div class="boxTitle"&gt;Participants&lt;/div&gt;Healthy adults recruited from postings.&lt;div class="boxTitle"&gt;Intervention&lt;/div&gt;Device or sham applied with finger pressure to the right or left sides, respectively, of the participants' lateral forehead, temple, and nasolabial fold. At the 24-hour visit, a larger area (3 × 3 matrix) at the central forehead was treated with the device, and the participants applied the device to their chins.&lt;div class="boxTitle"&gt;Main Outcome Measure&lt;/div&gt;Live blinded rater determination of local skin reaction scores (SRSs).&lt;div class="boxTitle"&gt;Results&lt;/div&gt;At the 5-minute skin assessment, the median SRS was 1 for all skin type and age groups. There was no median pain score higher than 1 for any age or skin type group. For the sham device, median SRSs were 0 at all time points for all age and skin type groups. Mean SRSs for the device and sham were significantly different only for the lateral forehead at 5 and 30 minutes (P = .04).&lt;div class="boxTitle"&gt;Conclusions&lt;/div&gt;The microneedle device appears to be safe and well tolerated in both sexes and various skin types and ages. Facial skin application of the device elicits mild, self-limited, and rapidly resolving erythema marginally greater than that associated with the sham control.&lt;div class="boxTitle"&gt;Trial Registration&lt;/div&gt;clinicaltrials.gov Identifier: NCT01257763&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">148</prism:volume>
      <prism:number xmlns:prism="prism">6</prism:number>
      <prism:startingPage xmlns:prism="prism">711</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">717</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/archdermatol.2012.280</prism:doi>
      <guid>http://archderm.jamanetwork.com/article.aspx?articleID=1149925</guid>
    </item>
  </channel>
</rss>